07.17.19

Sun Pharma Introduces Access Program for Patients Prescribed Xelpros in the US

Source: Sun Ophthalmics

Sun Ophthalmics has launched Xelpros Xpress, an access program for patients prescribed Xelpros (latanoprost ophthalmic emulsion) 0.005%. Xelpros recently became commercially available in the United States for the reduction of elevated IOP in people with open-angle glaucoma or ocular hypertension. Xelpros is the first and only benzalkonium chloride-free (BAK-free) form of latanoprost.

Through Xelpros Xpress, patients with a prescription can obtain Xelpros for a fixed price of $55 for a single month, or $37 per month for a 3-month supply, according to a company news release. Xelpros was approved by the FDA in September 2018.

“We created Xelpros Xpress to make it easier for patients to obtain Xelpros by offering direct access through pharmacies that distribute nationally and guarantee consistent cost plus high quality product and service,” Mark Hagler, senior vice president and head of ophthalmics, oncology and long-term care at Sun Pharma, said in the news release. “Xelpros Xpress allows us to help patients at every step of the product ordering and fulfillment process, ensuring that they have the best possible experience.”

Xelpros Xpress is designed to facilitate access to Xelpros without prior authorization, step therapy, copay cards, or coupons. The program also provides prompt fulfillment services and refill reminders for patients.

Xelpros is contraindicated in patients with known hypersensitivity to latanoprost, or any other product ingredients. The most common ocular adverse reactions reported in clinical trials (incidence ≥5%) for Xelpros are: eye pain/stinging, ocular hyperemia, conjunctival hyperemia, eye discharge, growth of eyelashes, and eyelash thickening.

Eye care professionals and patients can obtain more information about Xelpros and Xelpros Xpress at Xelpros.com.

 

Related Content